Intention to Treat Progress For Parkinson’s? — Itt Episode 28

At present, there is minimal and misleading knowledge of gastrointestinal dysfunction in Parkinson's disease among primary neurologists and gastroenterologists. This book reviews our current understanding of the GI involvement in PD, as many experiments suggest that the gut might be the site where the disease starts. Also discussed is how the gut dysfunction causes symptoms from the top (mouth) to the bottom (anal canal), and because of their frequency and severity, they contribute to disease progression and disability. In addition, the book covers the negative effects of small intestinal bacterial overgrowth (SIBO) and of a frequently silent stomach infection by Helicobacter pylori infection on the absorption of antiparkinsonian drugs, in turn causing motor fluctuations and inadequate treatment response.

At present, there is minimal and misleading knowledge of gastrointestinal dysfunction in Parkinson's disease among primary neurologists and gastroenterologists. This book reviews our current understanding of the GI involvement in PD, as many experiments suggest that the gut might be the site where the disease starts. Also discussed is how the gut dysfunction causes symptoms from the top (mouth) to the bottom (anal canal), and because of their frequency and severity, they contribute to disease progression and disability. In addition, the book covers the negative effects of small intestinal bacterial overgrowth (SIBO) and of a frequently silent stomach infection by Helicobacter pylori infection on the absorption of antiparkinsonian drugs, in turn causing motor fluctuations and inadequate treatment response.

Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein.

This book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from ‘bench to bedside’.